Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07569926 | Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence | recruiting | Phase 4 | 142 | Blue Earth DiagnosticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06908694 | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy(GAINPCCONTROL) | active not recruiting | Phase 4 | 20 | Hamilton Health Sciences CorporationOTHER |
| 1 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05700903 | Contributions to Hypertension With Androgen Deprivation Therapy(ARCH) | terminated | Phase 4 | 10 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07766122 | Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU(ECETEP) | not yet recruiting | Phase 4 | 30 | University Hospital, ToulouseOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04108208 | A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) | completed | Phase 4 | 75 | Janssen Research & Development, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07278362 | Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance | not yet recruiting | Phase 4 | 35 | University of MiamiOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06226129 | Gadopiclenol in Contrast Enhanced MRI of the Prostate | suspended | Phase 4 | 150 | Columbia UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07252726 | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | recruiting | Phase 4 | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06604442 | Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy | completed | Phase 4 | 62 | Blue Earth DiagnosticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07677566 | 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial(IUNU-PC-123) | not yet recruiting | Phase 4 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05722925 | Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET | active not recruiting | Phase 4 | 50 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03641560 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 4 | 52 | Astellas Pharma IncINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT06733350 | Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance | recruiting | Phase 4 | 600 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05753046 | Laparoscopic TAP Block During Robotic Assisted Laparoscopic Radical Prostatectomy for Improvement in Postoperative Pain(TAPBlock) | enrolling by invitation | Phase 4 | 94 | Corewell Health EastOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | active not recruiting | Phase 4 | 43 | AstraZenecaINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03016741 | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | active not recruiting | Phase 4 | 100 | Northwestern UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06627530 | COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer(COAction) | active not recruiting | Phase 4 | 144 | Brazilian Clinical Research InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06099093 | Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | recruiting | Phase 4 | 30 | Brigham and Women's HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06660862 | Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer. | not yet recruiting | Phase 4 | 80 | University of ChicagoOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT02651948 | Transperineal, MRI-guided, Prostate Biopsy | completed | Phase 4 | 90 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06479187 | PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer | active not recruiting | Phase 4 | 20 | Brigham and Women's HospitalOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05919329 | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | recruiting | Phase 4 | 80 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 24, 2025 | clinicaltrials |
| NCT06074510 | PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer(MIRROR) | active not recruiting | Phase 4 | 274 | Lantheus Medical ImagingINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07001709 | Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)(ENABLE) | recruiting | Phase 4 | 29 | Deventer ZiekenhuisOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05805436 | Preop Laxatives in Robotic Urologic Surgery | recruiting | Phase 4 | 240 | Chad R. TracyOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT01673984 | GP Extended Action Triptorelin(GREAT) | terminated | Phase 4 | 27 | IpsenINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT02405858 | A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | completed | Phase 4 | 51 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06784986 | Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study.(ARCO2) | recruiting | Phase 4 | 200 | Brazilian Institute of Robotic SurgeryOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04134208 | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer | terminated | Phase 4 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05568537 | Prostate MRI and Pylarify PSMA PET/CT | withdrawn | Phase 4 | 0 | Corewell Health EastOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT02918968 | Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | completed | Phase 4 | 206 | Astellas Pharma IncINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT02116582 | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 4 | 215 | Astellas Pharma Europe B.V.INDUSTRY | 5 | Dec 6, 2024 | clinicaltrials |
| NCT06706921 | 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer | recruiting | Phase 4 | 15 | VA Greater Los Angeles Healthcare SystemFED | 1 | Nov 27, 2024 | clinicaltrials |
| NCT03035032 | A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients | completed | Phase 4 | 107 | Astellas Pharma Singapore Pte. Ltd.INDUSTRY | 8 | Nov 26, 2024 | clinicaltrials |
| NCT05629494 | Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test(ADAPT-PSA) | recruiting | Phase 4 | 198 | Albany Medical CollegeOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT00953277 | Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer | completed | Phase 4 | 12 | Axogen CorporationINDUSTRY | 1 | Aug 12, 2024 | clinicaltrials |
| NCT03927391 | Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects(REDOSE) | completed | Phase 4 | 57 | Radboud University Medical CenterOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05957822 | Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery | unknown | Phase 4 | 148 | Konkuk University Medical CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06258486 | Ultrasound Guided Inguinal Indocyanine Green Injection to Identify and Pre-emptively Seal Lymphatic Leaks | unknown | Phase 4 | 100 | Kaiser PermanenteOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT05803096 | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | completed | Phase 4 | 143 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03432949 | Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC(TRANCE) | unknown | Phase 4 | 24 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06144099 | Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Non-cardiac Surgery | unknown | Phase 4 | 154 | Konkuk University Medical CenterOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT03824808 | Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery | terminated | Phase 4 | 21 | University of Missouri-ColumbiaOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT01995513 | Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients(PLATO) | completed | Phase 4 | 509 | PfizerINDUSTRY | 11 | Sep 18, 2023 | clinicaltrials |
| NCT06001619 | Prostate Medication, Metabolism and Gut Microbiota(PROMED) | recruiting | Phase 4 | 100 | Turku University HospitalOTHER_GOV | 1 | Aug 21, 2023 | clinicaltrials |
Data updated 6 hours agoSource updated Sep 29, 2026source: clinicaltrials